COVID-19 Vaccine Booster Targeting Omicron XBB.1.5 Variant Elicits Potent Neutralizing Antibody Responses Against Circulating SARS-CoV-2 Variants, Study Finds

Infectious Disease Advisor (4/15, Kuhns) reports, “The COVID-19 XBB.1.5-containing mRNA-1273 booster confers robust and diverse neutralizing antibody (nAb) responses against circulating SARS-CoV-2 variants, including JN.1, according to study results published in The Journal of Infectious Diseases.” These findings “support the strategy of updating COVID-19 vaccines to match antigenically-divergent variants and support the selection of the XBB.1.5-spike sequence for the 2023-2024 vaccine update.”